7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Zheng D et al. | The beneficial effect of Icariin on bone is diminished in osteoprotegerin-deficient mice. | 2012 | Bone | pmid:22551876 |
Dong W et al. | [Effect of alendronate on expressions of osteoprotegerin and receptor activator of nuclear factor κB ligand in mouse osteoblasts]. | 2012 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:23268391 |
Terpos E et al. | Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. | 2011 Nov-Dec | Clin. Exp. Rheumatol. | pmid:22032557 |
Arikan F et al. | C-telopeptide pyridinoline crosslinks of type I collagen, soluble RANKL, and osteoprotegerin levels in crevicular fluid of dental implants with peri-implantitis: a case-control study. | 2011 Mar-Apr | Int J Oral Maxillofac Implants | pmid:21483881 |
Crespi R et al. | Corticocancellous porcine bone in the healing of human extraction sockets: combining histomorphometry with osteoblast gene expression profiles in vivo. | 2011 Jul-Aug | Int J Oral Maxillofac Implants | pmid:21841997 |
Franke S et al. | Advanced glycation end products affect growth and function of osteoblasts. | 2011 Jul-Aug | Clin. Exp. Rheumatol. | pmid:21906430 |
Rezg R et al. | Inhibitors of vascular calcification as potential therapeutic targets. | 2011 Jul-Aug | J. Nephrol. | pmid:21688249 |
Reyes-GarcÃa R et al. | [Cardiovascular disease and bone metabolism]. | 2011 Aug-Sep | Endocrinol Nutr | pmid:21775224 |
Gurban CV and Mederle O | The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. | 2011 | Rom J Morphol Embryol | pmid:22119834 |
Millard SM et al. | Blockade of receptor-activated G(i) signaling in osteoblasts in vivo leads to site-specific increases in cortical and cancellous bone formation. | 2011 | J. Bone Miner. Res. | pmid:20939063 |
Ostrowska Z et al. | Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women. | 2011 | Postepy Hig Med Dosw (Online) | pmid:22100799 |
Gordon IK and Camphausen K | Research highlights. | 2011 | Biomark Med | pmid:21861664 |
Sood SK et al. | Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease. | 2011 | World J Surg | pmid:21748518 |
Stein SH and Tipton DA | Vitamin D and its impact on oral health--an update. | 2011 | J Tenn Dent Assoc | pmid:21748977 |
Xie H et al. | Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. | 2011 | Cardiovasc. Res. | pmid:21750093 |
Wang Y et al. | Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. | 2011 | J Orthop Surg Res | pmid:21752290 |
Jabbar S et al. | Plasma vitamin D and cytokines in periodontal disease and postmenopausal osteoporosis. | 2011 | J. Periodont. Res. | pmid:20731767 |
Lossdörfer S et al. | PTH(1-34)-induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells. | 2011 | Clin Oral Investig | pmid:20697756 |
Tipton DA et al. | Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. | 2011 | J. Periodont. Res. | pmid:20701670 |
Harada S and Takahashi N | [Control of bone resorption by RANKL-RANK system]. | 2011 | Clin Calcium | pmid:21814016 |
Nakamura M and Udagawa N | [Osteoporosis and RANKL signal]. | 2011 | Clin Calcium | pmid:21814019 |
Persson E and Lerner UH | The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts. | 2011 | J. Cell. Biochem. | pmid:21815197 |
Üstündağ M et al. | The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. | 2011 | J. Int. Med. Res. | pmid:21819709 |
Bellido M et al. | Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. | 2011 | Osteoarthr. Cartil. | pmid:21820069 |
Lawrie A et al. | Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. | 2011 | Am. J. Pathol. | pmid:21835155 |
Poulsen MK et al. | Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. | 2011 | Cardiovasc Diabetol | pmid:21838881 |
Markatseli AE et al. | Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women. | 2011 | Maturitas | pmid:21840657 |
Sudrová M et al. | Influence of long-term thromboprophylaxis with low-molecular-weight heparin (enoxaparin) on changes of bone metabolism markers in pregnant women. | 2011 | Clin. Appl. Thromb. Hemost. | pmid:20682598 |
Mamalis AA et al. | Chemical modification of an implant surface increases osteogenesis and simultaneously reduces osteoclastogenesis: an in vitro study. | 2011 | Clin Oral Implants Res | pmid:21070383 |
Vitoratos N et al. | Maternal circulating osteoprotegerin and soluble RANKL in pre-eclamptic women. | 2011 | Eur. J. Obstet. Gynecol. Reprod. Biol. | pmid:21074311 |
Belibasakis GN et al. | Oral biofilm challenge regulates the RANKL-OPG system in periodontal ligament and dental pulp cells. | 2011 | Microb. Pathog. | pmid:21075196 |
Wattanaroonwong N et al. | Oestrogen inhibits osteoclast formation induced by periodontal ligament fibroblasts. | 2011 | Arch. Oral Biol. | pmid:21035111 |
Osorio A et al. | Mineral-bone metabolism markers in young hemodialysis patients. | 2011 | Clin. Biochem. | pmid:21933667 |
Nybo M et al. | Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. | 2011 | Basic Clin. Pharmacol. Toxicol. | pmid:21726411 |
Fradet A et al. | Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. | 2011 | Cancer Res. | pmid:21734015 |
Campbell GM et al. | Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. | 2011 | Osteoporos Int | pmid:20480144 |
Kaneko K and Kawai S | [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis]. | 2011 | Nihon Rinsho Meneki Gakkai Kaishi | pmid:21720102 |
Karadag-Saygi E et al. | The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis. | 2011 | Gynecol. Endocrinol. | pmid:21627558 |
Taylor R et al. | Osteoclast formation and function in pigmented villonodular synovitis. | 2011 | J. Pathol. | pmid:21706481 |
Zhang Y et al. | Study of the mechanisms by which Sambucus williamsii HANCE extract exert protective effects against ovariectomy-induced osteoporosis in vivo. | 2011 | Osteoporos Int | pmid:20414641 |
Conaway HH et al. | Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor. | 2011 | J. Biol. Chem. | pmid:21715325 |
Hie M and Tsukamoto I | Vitamin C-deficiency stimulates osteoclastogenesis with an increase in RANK expression. | 2011 | J. Nutr. Biochem. | pmid:20444587 |
El-Shehaby A et al. | Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. | 2011 | J. Clin. Immunol. | pmid:21691937 |
Nich C et al. | Oestrogen deficiency modulates particle-induced osteolysis. | 2011 | Arthritis Res. Ther. | pmid:21696618 |
Belibasakis GN et al. | Porphyromonas gingivalis induces RANKL in T-cells. | 2011 | Inflammation | pmid:20446027 |
Clézardin P | [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications]. | 2011 | Bull Cancer | pmid:21700551 |
Celczyńska Bajew L et al. | The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. | 2011 | Kardiol Pol | pmid:21678294 |
Dzida G | [Decalcified bones, calcified heart?]. | 2011 | Kardiol Pol | pmid:21678295 |
Yang Q et al. | Plasma osteoprotegerin levels and long-term prognosis in patients with intermediate coronary artery lesions. | 2011 | Clin Cardiol | pmid:21678453 |
Toffoli B et al. | Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop. | 2011 | Atherosclerosis | pmid:21679949 |
de Moraes M et al. | Comparative immunohistochemical expression of RANK, RANKL and OPG in radicular and dentigerous cysts. | 2011 | Arch. Oral Biol. | pmid:21683340 |
Roshandel D et al. | Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men. | 2011 | Calcif. Tissue Int. | pmid:21964949 |
Davenport C et al. | Identifying coronary artery disease in men with type 2 diabetes: osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk. | 2011 | J. Hypertens. | pmid:21970938 |
Miyamoto K et al. | Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. | 2011 | J. Exp. Med. | pmid:22006978 |
Quemerais-Durieu MA et al. | [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)]. | 2011 | Ann. Endocrinol. (Paris) | pmid:22008272 |
Koo HM et al. | Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients. | 2011 | Atherosclerosis | pmid:22015178 |
Cao H et al. | Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation. | 2011 | Circ. J. | pmid:22001292 |
Scialla JJ et al. | Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. | 2011 | Clin J Am Soc Nephrol | pmid:21940840 |
Cianciolo G et al. | Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. | 2011 | Nephrol. Dial. Transplant. | pmid:20659908 |
Chasseraud M et al. | Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification. | 2011 | Ther Apher Dial | pmid:21426505 |
Duheron V et al. | Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. | 2011 | Proc. Natl. Acad. Sci. U.S.A. | pmid:21402940 |
Dimitrow PP et al. | The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. | 2011 | J. Heart Valve Dis. | pmid:21404893 |
Marques EA et al. | Effects of resistance and aerobic exercise on physical function, bone mineral density, OPG and RANKL in older women. | 2011 | Exp. Gerontol. | pmid:21316442 |
Chin A et al. | Effects of medicinal herb salvia miltiorrhiza on osteoblastic cells in vitro. | 2011 | J. Orthop. Res. | pmid:21319217 |
Mencej-BedraÄ S et al. | TNFRSF11B gene polymorphisms 1181G > C and 245T > G as well as haplotype CT influence bone mineral density in postmenopausal women. | 2011 | Maturitas | pmid:21411255 |
Lee JC et al. | Role of RANK-RANKL-OPG axis in cranial suture homeostasis. | 2011 | J Craniofac Surg | pmid:21415639 |
Mainini G et al. | Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women. | 2011 | Clin Exp Obstet Gynecol | pmid:22268274 |
Riksen EA et al. | Human osteoblastic cells discriminate between 20-kDa amelogenin isoforms. | 2011 | Eur. J. Oral Sci. | pmid:22243268 |
Yang Z et al. | [Effects of negative pressure on osteogenesis in human bone marrow-derived stroma cells cultured in vitro]. | 2011 | Zhongguo Gu Shang | pmid:22276514 |
Altinova AE et al. | Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. | 2011 | Scand. J. Clin. Lab. Invest. | pmid:21486111 |
Mercatali L et al. | Bone metastases detection by circulating biomarkers: OPG and RANK-L. | 2011 | Int. J. Oncol. | pmid:21491082 |
Stein SH et al. | Statins regulate interleukin-1β-induced RANKL and osteoprotegerin production by human gingival fibroblasts. | 2011 | J. Periodont. Res. | pmid:21463327 |
Liang QQ et al. | The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice. | 2011 | Bone | pmid:21466864 |
Honda K | Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes. | 2011 | J Oral Sci | pmid:21467819 |
Moldenhauer A et al. | Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity. | 2011 | Eur. J. Immunol. | pmid:21469100 |
Kim H et al. | Association between Wnt signaling pathway gene polymorphisms and bone response to hormone therapy in postmenopausal Korean women. | 2011 | Menopause | pmid:21471826 |
Mulcahy LE et al. | RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells. | 2011 | Bone | pmid:20854946 |
Aspenberg P et al. | Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening. | 2011 | Bone | pmid:20858557 |
Kurnatowska I et al. | Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. | 2011 | Nephron Clin Pract | pmid:20861651 |
de Souza Faloni AP et al. | Jaw and long bone marrows have a different osteoclastogenic potential. | 2011 | Calcif. Tissue Int. | pmid:20862464 |
Dimitri P et al. | Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. | 2011 | Bone | pmid:20932948 |
Yu H et al. | Overexpression of osteoprotegerin promotes preosteoblast differentiation to mature osteoblasts. | 2011 | Angle Orthod | pmid:20936961 |
Palaniswamy C et al. | Association of warfarin use with valvular and vascular calcification: a review. | 2011 | Clin Cardiol | pmid:21298649 |
Bostanci N et al. | Effect of periodontal treatment on receptor activator of NF-κB ligand and osteoprotegerin levels and relative ratio in gingival crevicular fluid. | 2011 | J. Clin. Periodontol. | pmid:21261673 |
Andersen GØ et al. | Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. | 2011 | Heart | pmid:21270073 |
Tsukamoto S et al. | Clinical significance of osteoprotegerin expression in human colorectal cancer. | 2011 | Clin. Cancer Res. | pmid:21270110 |
Monnouchi S et al. | The roles of angiotensin II in stretched periodontal ligament cells. | 2011 | J. Dent. Res. | pmid:21270461 |
Chang YH et al. | Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. | 2011 | Metab. Clin. Exp. | pmid:21251686 |
Bai P et al. | Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. | 2011 | Respir. Res. | pmid:22176920 |
Piedra M et al. | "Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density". | 2011 | BMC Med. Genet. | pmid:22185226 |
Kawaguchi H | [Approach for therapeutic targets of osteoarthritis]. | 2011 | Nippon Yakurigaku Zasshi | pmid:21747205 |
Cannon JG et al. | Follicle-stimulating hormone promotes RANK expression on human monocytes. | 2011 | Cytokine | pmid:21159522 |
Choe JY et al. | Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin. | 2011 | J. Rheumatol. | pmid:21159831 |
Mahoney DJ et al. | TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. | 2011 | Arthritis Rheum. | pmid:21162099 |
Nahidi L et al. | Osteoprotegerin in pediatric Crohn's disease and the effects of exclusive enteral nutrition. | 2011 | Inflamm. Bowel Dis. | pmid:20848544 |
Čolović M et al. | FGF-R3 and OPG expression in patient with multiple myeloma following systemic sclerosis: case report and review of the literature. | 2011 | Int. J. Hematol. | pmid:21207214 |
Hashiguchi D et al. | Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts. | 2011 | J Biomed Mater Res A | pmid:21171155 |
Li JY et al. | Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. | 2011 | Proc. Natl. Acad. Sci. U.S.A. | pmid:21187391 |
Hen K et al. | [Osteoprotegerin--a new atherosclerosis marker]. | 2011 | Pol. Merkur. Lekarski | pmid:22097184 |
Tang Y et al. | Porphyromonas endodontalis lipopolysaccharides induce RANKL by mouse osteoblast in a way different from that of Escherichia coli lipopolysaccharide. | 2011 | J Endod | pmid:22099899 |